Results for "consumer data right"
671-680 of 813 results for 'consumer data right'
FoFA amendments made
The Federal Government has made the 'time critical' FoFA amendments with new regulations saying that any financial product advice provided to an employer about their default superannuation fund is a financial service provided to a retail client. ...
ASIC's New Document Production Guidelines
ASIC has released its new Document Production Guidelines, which govern how it expects electronic and hard copy records to be produced in response to compulsory notices. ...
What does the change of government mean for Queensland's energy and resources sector?
With the results of the Queensland election having now been declared and the Labor Party invited to form government with the support of an independent Partner Ben Zillmann Managing Associate John Hedge and Associate Andrea Moffatt look at the key policies announced by Labor before the election that ...
FIRB changes to note from 1 July 2023
In this Insight, we outline and comment on the New Register and corresponding reporting obligations. ...
Revised Banking Code of Practice, innovation at the ASX and other corporate law developments
Revised Banking Code of Practice; innovation at the ASX; and other corporate law developments. ...
Interlocutory injunction refused based on 'doubtful' patent term extension
In the fight against patent infringement, challenging the validity of patent term extensions (PTEs) is increasingly becoming the weapon of choice for generic pharmaceutical companies. Since around the mid-2000s, patentees in pharmaceutical patent cases have typically been successful in bids for interlocutory injunctions, aiming to prevent the launch of generic products in Australia. The recent Biogen decision by the Federal Court is the latest in a trend of refusing interlocutory injunctions, and a clear indication the tide is turning. ...
Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...
Key considerations for renewable energy developers seeking private capital to fund expansion
As renewable energy developers look to expand their project pipelines and operational portfolios, many are turning to private capital sources to help fund their expansion plans. ...
FIRB shines the spotlight on tax issues
The Australian Government has announced that in applying the national interest test to future foreign investment applications it will be requiring investors to satisfy a series of tax compliance and disclosure obligations relating to the tax implications of the proposed investment and the ...